BEAUTY HEALTH CO/THE (SKIN) Forecast, Price Target & Analyst Ratings
NASDAQ:SKIN • US88331L1089
1.18 USD
+0.04 (+3.51%)
At close: Mar 9, 2026
1.18 USD
0 (0%)
After Hours: 3/9/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BEAUTY HEALTH CO/THE (SKIN).
Forecast Snapshot
Consensus Price Target
$2.00
+ 69.28% Upside
Next Earnings Forecast
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate-$0.05
Revenue Estimate79.313M
ChartMill Buy Consensus
51.43%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$2.00
Upside
+ 69.28%
From current price of $1.18 to mean target of $2.00, Based on 14 analyst forecasts
Low
$1.52
Median
$1.66
High
$3.68
Price Target Revisions
1 Month
0.00%
3 Months
1.29%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for SKIN. The average price target is 2 USD. This implies a price increase of 69.28% is expected in the next year compared to the current price of 1.18.
The average price target has been revised upward by 1.29% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
51.43%
SKIN was analyzed by 14 analysts. The buy percentage consensus is at 51. So analysts seem to be rather neutral about SKIN.
In the previous month the buy percentage consensus was at a similar level.
SKIN was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-21 | TD Cowen | Maintains | Hold -> Hold |
| 2025-09-22 | TD Cowen | Maintains | Hold -> Hold |
| 2025-09-19 | Roth Capital | Initiate | Buy |
| 2025-05-05 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-03-13 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2024-11-13 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2024-08-12 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2024-08-09 | Piper Sandler | Reiterate | Underweight -> Underweight |
| 2024-07-26 | Stifel | Maintains | Hold -> Hold |
| 2024-07-11 | Piper Sandler | Maintains | Underweight -> Underweight |
| 2024-05-13 | TD Cowen | Maintains | Hold -> Hold |
| 2024-05-13 | DA Davidson | Maintains | Buy -> Buy |
| 2024-05-10 | Piper Sandler | Maintains | Underweight -> Underweight |
| 2024-03-15 | DA Davidson | Maintains | Buy -> Buy |
| 2024-03-14 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2024-03-13 | TD Cowen | Maintains | Market Perform -> Market Perform |
| 2024-03-13 | Stifel | Reiterate | Hold -> Hold |
| 2024-03-13 | Piper Sandler | Reiterate | Underweight -> Underweight |
| 2024-02-29 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2023-11-15 | Jefferies | Downgrade | Buy -> Hold |
| 2023-11-14 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-14 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-11-14 | Benchmark | Downgrade | Buy -> Hold |
| 2023-11-14 | Stifel | Maintains | Hold -> Hold |
| 2023-11-14 | Raymond James | Downgrade | Market Perform -> Underperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 12, 2026
PeriodQ4 / 2025
EPS Estimate-$0.05
Revenue Estimate79.313M
Revenue Q2Q-5.01%
EPS Q2Q34.43%
Number of Analysts10
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.57%
EPS (1 Month)
0.00%
EPS (3 Months)
-11.20%
Next Earnings Summary
SKIN is expected to report earnings on 3/12/2026. The consensus EPS estimate for the next earnings is -0.05 USD and the consensus revenue estimate is 79.31M USD.
The next earnings revenue estimate has been revised downward by 0.57% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 365.9M 40.68% | 397.991M 8.77% | 334.294M -16.00% | 302.52M -9.50% | 315.9M 4.42% | 325.14M 2.92% | 353.94M 8.86% | 512.04M | |
| EBITDA YoY % growth | 7.48M 148.38% | -60.778M -912.54% | -10.297M 83.06% | 38.816M 476.96% | 39.268M 1.16% | 40.622M 3.45% | 105.06M 158.63% | N/A | |
| EBIT YoY % growth | -19.1M 47.81% | -93.017M -387.00% | -39.774M 57.24% | -24.596M 38.16% | -8.925M 63.71% | -18.598M -108.38% | 4.08M 121.94% | N/A | |
| Operating Margin | -5.22% | -23.37% | -11.90% | -8.13% | -2.83% | -5.72% | 1.15% | N/A | |
| EPS YoY % growth | 0.33 119.19% | 0.16 -51.52% | -0.18 -211.88% | -0.06 63.91% | -0.11 -69.75% | -0.19 -69.77% | 0.21 215.07% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.05 34.43% | -0.05 34.12% | -0.02 -173.68% | -0.04 50.89% | -0.02 57.22% | -0.04 22.59% | -0.03 -38.44% | -0.05 -15.39% | -0.03 -36.36% |
| Revenue Q2Q % growth | 79.313M -5.01% | 71.318M 2.47% | 81.398M 4.09% | 74.95M 6.08% | 83.966M 5.87% | 77.52M 8.70% | 87.108M 7.01% | 78.642M 4.93% | 86.904M 3.50% |
| EBITDA Q2Q % growth | 8.274M -70.04% | 7.446M 206.57% | 11.909M 78.60% | 10.149M -3.11% | 10.532M 27.29% | 4.692M -36.99% | 8.262M -30.62% | 11.322M 11.56% | 8.67M -17.68% |
| EBIT Q2Q % growth | -3.533M -90.28% | -3.162M 73.70% | 306K 111.33% | -2.219M 64.46% | -1.081M 69.40% | -9.282M -193.55% | -4.794M -1,666.67% | -5.406M -143.68% | -6.63M -513.21% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-1.31%
EPS Next 5 Year
33.71%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-0.97%
Revenue Next 5 Year
1.40%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
35.69%
EBIT Next 5 Year
34.66%
BEAUTY HEALTH CO/THE / SKIN Forecast FAQ
What do analysts expect the price target to be for BEAUTY HEALTH CO/THE (SKIN)?
14 analysts have analysed SKIN and the average price target is 2 USD. This implies a price increase of 69.28% is expected in the next year compared to the current price of 1.18.
When does BEAUTY HEALTH CO/THE (SKIN) report earnings?
BEAUTY HEALTH CO/THE (SKIN) will report earnings on 2026-03-12, after the market close.
Can you provide the consensus estimates for BEAUTY HEALTH CO/THE next earnings?
The consensus EPS estimate for the next earnings of BEAUTY HEALTH CO/THE (SKIN) is -0.05 USD and the consensus revenue estimate is 79.31M USD.
What is the expected long term growth rate for SKIN stock?
The expected long term growth rate for BEAUTY HEALTH CO/THE (SKIN) is -0.97%.